Association of side effects to medication adherence of antiepileptic drug use in epileptic patients

  • Iin Ernawati Department of Clinical Pharmacy, Akademi Farmasi Surabaya, Surabaya, 60231, Indonesia
  • Oktaviani Putri Wyono Diploma III in Pharmacy, Akademi Farmasi Surabaya, Surabaya, 60231, Indonesia
  • Fitria Dewi Yunitasari Department of Clinical Pharmacy, Akademi Farmasi Surabaya, Surabaya, 60231, Indonesia
  • Erwindy Yastika Pradani Department of Neurology, Faculty of Medicine, Airlangga Hospital University, Surabaya, 60231, Indonesia
  • Wardah Rahmatul Islamiyah Department of Neurology, Faculty of Medicine, Airlangga Hospital University, Surabaya, 60231, Indonesia
DOI: https://doi.org/10.35814/jifi.v22i1.1269

Abstract

Epilepsy is a chronic neurological disorder with symptoms characterized by seizures, arising spontaneously with brief episodes with the main symptom of decreased or loss of consciousness. This study aims to examine the effect of side effects of medication adherence to antiepileptic drug use in epilepsy patients. This research is an observational study that was analyzed using quantitative descriptive methods in Neurology patients at the Airlangga University Hospital from March until May 2022. Side effects were measured using the LAEP (Liverpool Adverse Effects Profile) questionnaire and adherence was measured using a pill count. Results showed that the influence of side effects on medication adherence (pill count method) to antiepileptic drugs using linear regression, it is known that the P-value is 0.501. There is no significant relationship between the category of side effects and medication adherence to antiepileptic drugs. Another factor that influences compliance with medication use is the appearance of seizures. Based on the results of this study, it is known that the greater the frequency of seizures, the more likely patients are to be non-compliant (P-value 0.006). To increase adherence, it is necessary to pay attention to other factors such as knowledge, economy, and type of therapy in epilepsy patients so that therapeutic outcomes can be achieved.

References

[1] J.P. Leach, R.J. Davenport. Neurological Disease. In: Walker, B.R., Colledge, NR, Ralston, SH, Penman, ID. (Eds). Davidson’s Principles & Practice of Medicine 22 th ed.; London: Churchill Livingstone Elsevier. 2014

[2] M. Aminoff, V. Douglas. Nervous System Disorders. In: Papadakis MA, McPhee SJ, Rabow MW. (Eds). Current Medical Diagnosis & Treatment 56th ed. ; Pp 983-990. New York: McGraw Hill Education. 2017

[3] E.J. Corwin. Patofisiologi. ed 1. Pakaryaningsih E, editor. Jakarta: EGC; pp. 172–175 . 2001

[4] World Health Organization. Epilepsy in the WHO South-East Asian Region. 2021. Diakses 7 Februari 2022; https://www.who.int/publications-detail- redirect/9241563036

[5] World Health Organization. Epilepsy A Public Health Imperative. Vol. 1. 2019. Diakses tanggal 7 Februari 2022; https://www.who.int/publications/i/item/e pilepsy-a-public-health-imperative

[6] C.E. Elger, D. Schmidt. “Modern management of epilepsy: a practical approach” [published correction appears in Epilepsy Behav. Vol. 13, no. 3:pp. 575. 2008

[7] D. Dash, V. Aggarwal, R. Joshi, M.V. Padma, M. Tripathi. “Effect of reduction of antiepileptic drugs in patients with drug- refractory epilepsy”. Seizure. vol. 27:pp. 25- 29. 2015

[8] M.E. Shams, E.A. Barakat. “Measuring the rate of therapeutic adherence among outpatients with T2DM in Egypt”. Saudi Pharm. J. vol 18. no. 4: pp.225. 2010

[9] R. Gurumurthy, K. Chanda, Sarma. “An evaluation of factors affecting adherence to antiepileptic drugs in patients with epilepsy: a cross-sectional study”. Singapore Med J. vol. 58. no. 2: pp. 98-102. 2017

[10] M. A. Elsayed, N.M. El-Sayed, S. Badi, M.H. Ahmed. “Factors affecting adherence to antiepileptic medications among Sudanese individuals with epilepsy: A cross-sectional survey”. J Family Med Prim Care. vol. 8. no. 7: pp. 2312-2317. 2019

[11] A.E.S. Wahab, M. Al Omar, M.M.A.M. Altabakha. “Adherence to Antiepileptic Drugs among Patients Attending the Neuro Spinal Hospital in the United Arab Emirates”. J Pharm Bioallied Sci. Vol. 12. No. 4 :pp. 499-507. 2020

[12] C.A. Hovinga, M.R. Asato, R. Manjunath, J.W Wheles, S.J. Phelps, R.D. Sheth. “Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians”. Epilepsy Behav. Vol. 13. no. 2:pp. 316–22. 2008

[13] Ernawati, Iin et al. “How to Improve Clinical Outcome of Epileptic Seizure Control Based on Medication Adherence? A Literature Review.” Open access Macedonian journal of medical sciences vol. 6, no. 6 pp. 1174-1179. 2018,

[14] A. Budikayanti, L.M. Qadri, Z. Syeban, L.A. Indrawati, F. Octaviana. “Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile”. Neurol Res Int. 2018; 2018:8490639.

[15] I. Ernawati, E.I. Lubada, R. Lusiyani, R.A. Prasetya. “Association of adherence measured by self-reported pill count with achieved blood pressure level in hypertension patients: a cross-sectional study”. Clinical Hypertension, vol 28. pp. 12. 2022

[16] H. Permana. “Tingkat Pengetahuan, Sikap, dan Persepsi Mengenai Epilepsi antara Masyarakat Pedesaan dan Perkotaan di Padang”. Heal Med J. Vol. 3, no. 1: pp. 14–9.2020

[17] Y.B. Beyene, F.B. Daba, K.K. Goro, B.S Senbeta. “Drug therapy problems and predicting factors among
ambulatory epileptic patients in Jimma Medical Center, Southwest Ethiopia”. PLoS ONE. Vol. 17 no. 4: e0267673. 2022

[18] S. Kumar, M.B. Singh, A. Kumar, M.V. Padma Srivastava, V. Goyal. “Medication Adherence in Indian Epilepsy Patients”. Ann Indian Acad Neurol. vol. 24 no. 4:pp. 501-505. 2012

[19] J.A. French and T.A. Pedley. “Initial management of epilepsy”. N Engl J Med. vol. 359, no. 2: pp. 166–176. 2008

[20] M.B. Ayalew, E.A. Muche. “Patient reported adverse events among epileptic patients taking antiepileptic drugs”. SAGE Open Med. Vol. 6: 2050312118772471. 2018

[21] J.A. Cramer, S. Mintzer, J. Wheless, et al. “Adverse effects of antiepileptic drugs: a brief overview of important issues”. Expert Rev Neurother. vol. 10 no. 6: pp. 885–891. 2010

[22] D. Schmidt. “Efficacy of new antiepileptic drugs”. Epilepsy Curr. 2011; 11(1): 9–11.

[23] P. Perucca, J. Carter, V. Vahle, et al. “Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy”. Neurology. vol. 72 no. 14: pp. 1223–1229. 2009

[24] S.K. Peasah, J. Fishman, D. Ems. et al. “Association Between Adverse Events and Discontinuation of Antiepileptic Drugs Among Drug-Naïve Adults with Epilepsy”. Drugs-Real World Outcomes. vol. 8. pp. 5–14. 2021

[25] J. Rupa, T. Manjari, G. Pooja, G.G. Sheffali, Y. Kumar. “Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy”. Indian Journal of Medical Research. vol. 145 (3): pp. 317-326. 2017

[26] H.T. Pham, M.H. Tran, N.Q. Nguyen et al. “Role of clinical pharmacists in epilepsy management at a general hospital in Vietnam: a before-and-after study”. J of Pharm Policy and Pract. Vol. 14: pp. 109. 2021

[27] A.M. Das, L. Ramamoorthy, S.K. Narayan, V. Wadvekar, K.T Harichandrakumar. “Adherence to Antiepileptic Regime: A Cross-sectional Survey”. Neurol India, vol. 68:pp. 856-60. 2020

[28] M.R. Di Matteo, C.D. Sherbourne, R.D. Hays, L. Ordway, R.L. Kravitz, E.A. McGlynn et al. “Physicians’ characteristics influence patients’ adherence to medical treatment: Results from the medical outcomes study”. Health Psychol. Vol. 12: pp. 93–102. 1993

[29] S.J Benner, R.J. Glynn, H. Mogun, P.J. Neumann, M.C. Weinstein, J. Avorn. “Long-term persistence in use of statin therapy in elderly patients”. JAMA. Vol 288: pp. 455– 61.2002

[30] Golin, Carol E et al. “A prospective study of predictors of adherence to combination antiretroviral medication.” Journal of general internal medicine vol. 17,10: pp. 756-65. 2002

[31] A.A Sunny, R.S Iyer, S.G. Kumaran, N.G. Bunshaw, K. Shanmugham, U. Govindaraj. “Affordability, availability and tolerability of anti-seizure medications are better predictors of adherence than beliefs: Changing paradigms from a low resource setting”. Seizure, vol. 83: pp. 208–215. 2020

[32] H.H Martins, N.B. Alonso, L.M.F.F. Guilhoto, M. Guaranha, E.M.T Yacubian. “Adherence to treatment in patients with juvenile myoclonic epilepsy: correlation with quality of life and adverse effects of medication”. JECN, vol. 15:pp. 192–6. 2015

[33] Gabr, Wael M, and Mohamed E E Shams. “Adherence to medication among outpatient adolescents with epilepsy.” Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 23,1: pp. 33-40. 2015

[34] Cutler, Rachelle Louise et al. “Economic impact of medication non-adherence by disease groups: a systematic review.” BMJ open vol. 8,1 e016982. 21 Jan. 2018
Published
2024-04-30
How to Cite
ERNAWATI, Iin et al. Association of side effects to medication adherence of antiepileptic drug use in epileptic patients. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 22, n. 1, p. 80-86, apr. 2024. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1269>. Date accessed: 18 nov. 2024. doi: https://doi.org/10.35814/jifi.v22i1.1269.
Citation Formats
Issue
Vol 22 No 1 (2024): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.